Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
A Patient with TP53 Germline Mutation Developed Bowen’s Disease and Myelodysplastic Syndrome with Myelofibrosis after Chemotherapy against Ovarian Cancer
Kageaki KURIBAYASHITakuya MATSUNAGAToshio SAKAIYuko WADAKumiko TATENOKazuyuki MURASEAkihito FUJIMIRishu TAKIMOTOTakeshi TERUIJunji KATOAya SASAKIMasaaki SATOHYoshiro NIITSU
著者情報
ジャーナル オープンアクセス

2005 年 44 巻 5 号 p. 490-495

詳細
抄録

Here we report a case of myelodysplastic syndrome (MDS) with myelofibrosis associated with Bowen’s disease. A female patient had undergone an operation and chemotherapy for ovarian cancer when she was 65 years old, and she developed MDS at the age of 70 years old. PCR-single strand conformation polymorphism (SSCP) analysis of peripheral blood mononuclear cells, a Bowen’s disease lesion, and normal skin showed an abnormal peak in TP53 exon5. Direct sequencing revealed that they all had missense mutation in codon 175 (G to A) of arginine switched to histidine, suggesting a germline mutation of TP53. It was speculated that p53 function was lost by TP53 germline mutation with the loss of a wild type allele induced by the chemotherapy against ovarian cancer, leading to the development of MDS. No therapeutic effects of low dose melphalan or cyclosporine A on MDS were observed, however one month of 30 mg/day prednisolone administration induced a hematological response.

著者関連情報
© 2005 by The Japanese Society of Internal Medicine
前の記事 次の記事
feedback
Top